Drug Profile
LW 50020
Alternative Names: Luivac; LW-50050; PaspatLatest Information Update: 01 Mar 2022
Price :
$50
*
At a glance
- Originator Luitpold Pharmaceuticals
- Developer American Regent; Daiichi Sankyo Company
- Class Antibacterials; Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bacterial infections; Respiratory tract infections
Most Recent Events
- 11 Sep 2019 Daiichi Sankyo completes a phase III trial in Respiratory tract infections (Prevention, In adults) in Italy, prior to September 2019 (EudraCT2016-000978-38)
- 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
- 06 Jul 2016 Phase-III clinical trials in Respiratory tract infections (Prevention, In adults) in Italy (PO) (EudraCT2016-000978-38)